UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 31, 2014
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
333-148922 |
26-0690857 |
(State or other jurisdiction of
incorporation or organization) |
(Commission File Number) |
IRS Employer
Identification No.) |
c/o Janssen Labs @QB3
953 Indiana Street
San Francisco, CA |
94107 |
(Address of Principal Executive Offices) |
(Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 |
Entry into a Material Definitive Agreement |
On July 31, 2014, Amarantus BioScience
Holdings, Inc. (the “Company”) entered into an Option Agreement (the “Agreement”) with the Universität
Leipzig (“Leipzig”) pursuant to which the Company was granted an option to obtain an exclusive license (with the right
to sublicense) in the patent rights relating to PCT Application No. PCT/EP2010/000702 entitled “Vector(s) Containing an Inducible
Gene Encoding a CDK4/CDK6 Inhibitor Useful for Treating Neurodegenerative Disorders or Diseases Associated with an Unscheduled
Activation of the Cell Cycle”. The term of the option is 12 months which may be extended by the Company for an additional
six months upon payment of an extension fee of $5,000. The Agreement provides for an option fee of $10,000 within 10 days of the
date of the Agreement.
The Agreement contemplates that the parties
will use good faith efforts to execute a sponsored research agreement and provides that upon exercise of the option, the parties
will use good faith efforts to execute a license agreement within three months of the exercise of the option.
The Company released a press release in
connection with the foregoing, a copy of which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press release dated August 1, 2014 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
AMARANTUS BIOSCIENCE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
Date: August 6, 2014 |
|
By: |
/s/ Gerald E. Commissiong |
|
|
|
|
|
Name: Gerald E. Commissiong |
|
|
|
|
|
Title: Chief Executive Officer |
|
Amarantus Acquires Exclusive Option to License Alzheimer's Therapeutic
IP of Dr. Thomas Arendt From University of Leipzig
SAN FRANCISCO and GENEVA, Aug. 1, 2014
(GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the discovery and
development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration
and apoptosis, today announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic
concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3rd Alzheimer's focused
Coalition for Concussion Treatment Summit. Under the terms of the agreement, the Company and the University of Leipzig will have
12 months to negotiate a definitive license agreement, and the Company will work with Dr. Arendt to establish a Sponsored Research
Agreement to outline the advancement of the therapeutic strategies into human clinical development.
"We are extremely pleased to enter
into this agreement that further positions Amarantus within the cell cycle dysregulation field in Alzheimer's disease," said
Gerald E. Commissiong, President & CEO of Amarantus. "We believe new concepts and ideas are required to make progress
in treating this devastating disorder, and we believe Dr. Arendt's pioneering work that led to LymPro also has therapeutic applications.
We look forward to working with the University to execute definitive agreements."
Dr. Arendt has filed international
patent applications on the concepts of modulating the expression of P16 in the brains of patients of Alzheimer's disease using
gene therapy. P16 is a cell cycle protein that assists in maintaining and nurturing synaptic connections that is hypothesized to
be at the root of Alzheimer's pathology. The Company is currently developing an Alzheimer's blood diagnostic LymPro Test(R) capable
of identifying cell cycle dysregulation by harvesting peripheral blood lymphocytes. This option agreement opens the possibility
of a targeted therapeutic on those Alzheimer's patients that have tested positive for LymPro.
About Alzheimer's disease
It is estimated that over 5.4 million
people in the United States suffer from Alzheimer's disease and over 500,000 patients are diagnosed annually, with nearly one in
eight older Americans affected by the disease. Alzheimer's is the third leading cause of death in the United States. The estimated
cost of unpaid care in the United States is estimated at over $210 billion annually and the total payments for care are estimated
at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. It is estimated that the cost to the United
States will exceed $1.4 trillion by 2050.
About Amarantus BioScience Holdings,
Inc.
Amarantus BioScience Holdings (AMBS)
is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related
apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa
induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)")
for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived
Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns
intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors
("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please
visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Certain statements, other than purely
historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating
results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking
statements generally are identified by the words believes," project," expects," anticipates," estimates,"
intends," strategy," plan," may," will," would," will be," will continue," will likely
result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability
to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic
conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting
principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance
should not be placed on such statements.
Contact:
Amarantus Bioscience Holdings, Inc.:
Aimee Boutcher, Investor Relations
408.737.2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024